60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced its entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against the vector-borne bacteria, Borrelia (Lyme disease) and Bartonella, in cell culture. Together with Babesia, these three pathogens are known as the “3Bs” in the Lyme disease community.

Read more at globenewswire.com